[an error occurred while processing this directive] | [an error occurred while processing this directive]
Current status and prospects of treatment of newly-diagnosed nasopharyngeal carcinoma with distant metastasis
Ni Mengshan, Ying Hongmei
Department of Radiation Oncology, Fudan University Shanghai Cancer Center/ Department of Oncology, Shanghai Medical College, Fudan University/ Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China
Abstract From synchronous metastasis to metachronous metastasis and from oligometastasis to disseminated metastasis, distant metastatic nasopharyngeal carcinoma (stage IVB) has great heterogeneity. The prognosis of stage IVB nasopharyngeal carcinoma patients with distant metastases is closely related to the anatomical characteristics of metastases. Therefore, it is necessary to subdivide M1 stage to lay the foundation for individualized treatment of patients with metastatic nasopharyngeal carcinoma. In addition to systemic chemotherapy, the primary tumors and metastatic lesions should be considered during the treatment of newly-diagnosed metastatic nasopharyngeal carcinoma. Currently, there is a lack of recognized treatment modes for newly-diagnosed stageⅣB nasopharyngeal carcinoma, and more studies are needed to evaluate the clinical benefits of different treatment methods.
Ni Mengshan,Ying Hongmei. Current status and prospects of treatment of newly-diagnosed nasopharyngeal carcinoma with distant metastasis[J]. Chinese Journal of Radiation Oncology, 2021, 30(9): 979-983.
Ni Mengshan,Ying Hongmei. Current status and prospects of treatment of newly-diagnosed nasopharyngeal carcinoma with distant metastasis[J]. Chinese Journal of Radiation Oncology, 2021, 30(9): 979-983.
[1] Liao W, Tian M, Chen N.Characteristic and novel therapeutic strategies of nasopharyngeal carcinoma with synchronous metastasis[J]. Cancer Manag Res, 2019, 11:8431-8442.DOI:10.2147/CMAR.S219994. [2] Zou X, You R, Liu H, et al.Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment[J]. Eur J Cancer, 2017, 77:117-126.DOI:10.1016/j.ejca.2017.02.029. [3] Chen YP, Chan ATC, Le QT, et al.Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192):64-80.DOI:10.1016/s0140-6736(19)30956-0. [4] Pan CC, Wu PH, Yu JR, et al.Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation[J]. Eur J Radiol, 2012, 81(4):e473-e477.DOI:10.1016/j.ejrad.2011.05.037. [5] Jin Y, Cai YC, Cao Y, et al.Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes[J]. J Surg Oncol, 2012, 106(3):322-326.DOI:10.1002/jso.23034. [6] Huang CJ, Leung SW, Lian SL, et al.Patterns of distant metastases in nasopharyngeal carcinoma[J]. Kaohsiung J Med Sci, 1996, 12(4):229-234. [7] Zhao CL, Qian GQ, Chen XY, et al.Retrograde analysis of clinical characteristics of bone metastasis in 1,031 cases of preliminarily diagnosed nasopharyngeal carcinoma[J]. Asian Pac J Cancer Prev, 2014, 15(8):3785-3788.DOI:10.7314/apjcp.2014.15.8.3785. [8] Shen LJ, Wang SY, Xie GF, et al.Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis:time to expand the M categorization system[J]. Chin J Cancer, 2015, 34(10):450-458.DOI:10.1186/s40880-015-0031-9. [9] Shen L, Dong J, Li S, et al.M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma[J]. Oncologist, 2015, 20(3):291-298.DOI:10.1634/theoncologist.2014-0206. [10] Sun XS, Liang YJ, Liu SL, et al.Subdivision of nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis for prediction of survival and treatment guidance[J]. Cancer Res Treat, 2019, 51(4):1259-1268.DOI:10.4143/crt.2018.652. [11] 蓝玉宏,田允铭,白力,等.初治转移鼻咽癌疗后预后评分模型建立及分层治疗研究[J]. 中华放射肿瘤学杂志, 2015, 24(4):421-426.DOI:10.3760/j.issn.1004-4221.2015.04.017. Lan YH, Tian YM, Bai L, et al.Establishment of prognostic scoring model and hierarchical treatment of newly diagnosed metastatic nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2015, 24(4):421-426.DOI:10.3760/j.issn.1004-4221.2015.04.017. [12] Li W, Bai YT, Wu M, et al.Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver:Propensity score matching analysis[J]. Oncotarget, 2017, 8(32):52132-52141.DOI:10.18632/oncotarget.10383. [13] Palacios-Eito A, García-Cabezas S.Oligometastatic disease, the curative challenge in radiation oncology[J]. World J Clin Oncol, 2015, 6(4):30-34.DOI:10.5306/wjco.v6.i4.30. [14] Zhang L, Huang Y, Hong S, et al.Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2016, 388(10054):1883-1892.DOI:10.1016/s0140-6736(16)31388-5. [15] Grau JJ, Caballero M, Verger E, et al.Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients[J]. Acta Otolaryngol, 2009, 129(11):1294-1299.DOI:10.3109/00016480802590451. [16] Gibson MK, Li Y, Murphy B, et al.Randomized phase Ⅲ evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395):an intergroup trial of the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2005, 23(15):3562-3567.DOI:10.1200/jco.2005.01.057. [17] Samlowski WE, Moon J, Kuebler J P, et al.Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN):a Southwest Oncology Group Phase Ⅱ study[J]. Cancer Invest, 2007, 25(3):182-188.DOI:10.1080/07357900701209061. [18] Jin Y, Shi YX, Cai XY, et al.Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma[J]. J Cancer Res Clin Oncol, 2012, 138(10):1717-1725.DOI:10.1007/s00432-012-1219-x. [19] Rusthoven CG, Lanning RM, Jones BL, et al.Metastatic nasopharyngeal carcinoma:Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy[J]. Radiother Oncol, 2017, 124(1):139-146.DOI:10.1016/j.radonc.2017.03.019. [20] Chen MY, Jiang R, Guo L, et al.Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis[J]. Chin J Cancer, 2013, 32(11):604-613.DOI:10.5732/cjc.013.10148. [21] Tian YM, Huang WZ, Lan YH, et al.Prognostic model and optimal treatment for patients with stage IVc nasopharyngeal carcinoma at diagnosis[J]. Sci Rep, 2019, 9(1):19272.DOI:10.1038/s41598-019-55586-w. [22] 汪琛,李金高,邹嵩,等.初治转移性鼻咽癌预后因素及治疗模式探讨[J]. 中山大学学报(医学科学版), 2014, 35(6):880-888. Wang C, Li JG, Zou S, et al.Prognostic factors and treatment mode of newly diagnosed metastatic nasopharyngeal carcinoma[J]. J Sun Yat-Sen Univ (Med Sci ed), 2014, 35(6):880-888. [23] Tian YH, Zou WH, Xiao WW, et al.Oligometastases in AJCC stage IVc nasopharyngeal carcinoma:a subset with better overall survival[J]. Head Neck, 2016, 38(8):1152-1157.DOI:10.1002/hed.24345. [24] Ma BB, Poon TC, To KF, et al.Prognostic significance of tumor angiogenesis, Ki67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study[J]. Head Neck, 2003, 25(10):864-872.DOI:10.1002/hed.10307. [25] Li Z, Li Y, Yan S, et al.Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma[J]. OncoTargets Ther, 2017, 10:5445-5458.DOI:10.2147/OTT.S141538. [26] Ma BBY, Lim WT, Goh BC, et al.Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma:an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)[J]. J Clin Oncol, 2018, 36(14):1412-1418.DOI:10.1200/jco.2017.77.0388. [27] Hsu C, Lee S H, Ejadi S, et al.Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma:results of the KEYNOTE-028 study[J]. J Clin Oncol, 2017, 35(36):4050-4056.DOI:10.1200/jco.2017.73.3675. [28] Fang W, Yang Y, Ma Y, et al.Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10):1338-1350.DOI:10.1016/s1470-2045(18)30495-9. [29] 于金明,滕菲菲.放疗与免疫治疗联合应用的相关机制及研究进展[J]. 中国肿瘤临床,2014, 41(9):547-550.DOI:10.3969/j.issn.1000-8179.20140527. Yu JM, Teng FF.Mechanism and research progress of combined application of radiotherapy and immunotherapy[J]. Chin J Clin Oncol, 2014, 41(9):547-550.DOI:10.3969/j.issn.1000-8179.20140527. [30] Zeng L, Tian YM, Huang Y, et al.Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis:therapeutic approaches and prognostic factors[J]. PLoS One, 2014, 9(9):e108070.DOI:10.1371/journal.pone.0108070. [31] 田允铭,韩非,曾雷,等.寡转移状态下初治鼻咽癌的预后及治疗模式探讨[J]. 中华放射肿瘤学杂志, 2016, 25(11):1156-1160.DOI:10.3760/cma.j.issn.1004-4221.2016.11.003. Tian YM, Han F, Zeng L, et al.Study on the prognosis and treatment mode of newly treated nasopharyngeal carcinoma in oligometastasis[J]. Chin J Radiat Oncol, 2016, 25(11):1156-1160.DOI:10.3760/cma.j.issn.1004-4221.2016.11.003. [32] Hu JY, Kong L, Gao J, et al.Use of radiation therapy in metastatic nasopharyngeal cancer improves survival:a SEER analysis[J]. Sci Rep, 2017, 7(1):721.DOI:10.1038/s41598-017-00655-1. [33] Hu SX, He XH, Dong M, et al.Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis[J]. Med Oncol, 2015, 32(9):224.DOI:10.1007/s12032-015-0663-2. [34] Comen E, Norton L, Massagué J.Clinical implications of cancer self-seeding[J]. Nat Rev Clin Oncol, 2011, 8(6):369-377.DOI:10.1038/nrclinonc.2011.64. [35] Siva S, MacManus MP, Martin RF, et al.Abscopal effects of radiation therapy:a clinical review for the radiobiologist[J]. Cancer Lett, 2015, 356(1):82-90.DOI:10.1016/j.canlet.2013.09.018. [36] 黄爽,陈媛媛,姜锋,等.初治寡转移鼻咽癌患者原发灶根治性放疗疗效分析[J]. 中华放射肿瘤学杂志, 2018, 27(1):35-39.DOI:10.3760/cma.j.issn.1004-4221.2018.01.007. Huang S, Chen YY, Jiang F, et al.Curative effect analysis of primary tumor radical radiotherapy in patients with newly treated oligo metastatic nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2018, 27(1):35-39.DOI:10.3760/cma.j.issn.1004-4221.2018.01.007. [37] Setton J, Wolden S, Caria N, et al.Definitive treatment of metastatic nasopharyngeal carcinoma:report of 5 cases with review of literature[J]. Head Neck, 2012, 34(5):753-757.DOI:10.1002/hed.21608. [38] 唐秋,胡巧英,朴永锋,等.不同方式治疗 87例鼻咽癌放疗后肺寡转移患者的疗效分析[J]. 中华肿瘤杂志, 2016, 38(3):218-222.DOI:10.3760/cma.j.issn.0253-3766.2016.03.011. Tang Q, Hu QY, Piao YF, et al.Analysis of curative effect of different treatment methods on 87 patients with lung oligometastasis after radiotherapy of nasopharyngeal carcinoma[J]. Chin J Oncol, 2016, 38(3):218-222.DOI:10.3760/cma.j.issn.0253-3766.2016.03.011.
2021, Vol. 30 
